WuXi   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2000)

Organization Overview

First Clinical Trial
2016
NCT02954172
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

D3 Bio (Wuxi) Co., Ltd | WuXi CDS Clinical Research (Shanghai) Co.Ltd. | WuXi Clinical

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: WuXi (3) Acquired (1)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (1 trial)

hydroxyprogesterone (Delalutin) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 2 Trials (5)

Key: WuXi (2) Acquired (3)

anx005 (1 trial)

fluzoparib (1 trial)

immune globulin (human) (Gamastan) (1 trial)

tripterygium wilfordii (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (2)

d3l-001 (1 trial)

d3s-001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 11